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Highlights 
Fgfr2c overexpression causes craniofacial hypoplasia, microtia and cleft palate.
Craniosynostosis is not associated with Fgfr2c overexpression.
Mutant coronal sutures have increased levels of MAPK/ERK signalling.
Fgfr2c overexpression partially rescues craniosynostosis in the Crouzon mouse.
Summary statement 
Increased levels of FGFR2c cause craniofacial bone hypoplasia, microtia and cleft palate, but not 
craniosynostosis. Introduction of an extra Fgfr2c allele into a mouse model for Crouzon syndrome 
partially rescues the craniosynostosis phenotype. 
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Abstract 
FGFR2c regulates many aspects of craniofacial and skeletal development. Mutations in the FGFR2 
gene are causative for multiple forms of syndromic craniosynostosis, including Crouzon syndrome. 
Paradoxically, mouse studies have shown that both the activation (Fgfr2cC342Y; a mouse model for 
human Crouzon syndrome), as well as the removal (Fgfr2cnull) of the FGFR2c isoform can drive 
suture abolishment. This study aims to address the downstream effects of pathogenic FGFR2c 
signalling by studying the effects of Fgfr2c overexpression. 
Conditional overexpression of Fgfr2c (R26RFgfr2c;act) results in craniofacial hypoplasia as well as 
microtia and cleft palate. Contrary to Fgfr2cnull and Fgfr2cC342Y, Fgfr2c overexpression is insufficient 
to drive onset of craniosynostosis. Examination of the MAPK/ERK pathway in the embryonic sutures 
of Fgfr2cC342Y and R26RFgfr2c;act mice reveals that both mutants have increased pERK expression. The 
contrasting phenotypes between Fgfr2cC342Y and R26RFgfr2c;act mice prompted us to assess the impact 
of the Fgfr2c overexpression allele on the Crouzon mouse (Fgfr2cC342Y), in particular to the coronal 
suture. Our results demonstrate that Fgfr2c overexpression is sufficient to partially rescue 
craniosynostosis through increased proliferation and reduced osteogenic activity in E18.5 Fgfr2cC342Y 
embryos. 
This study demonstrates the intricate balance of FGF signalling required for correct calvarial bone and 
suture morphogenesis, and that increasing the expression of the wild-type FGFR2c isoform may be a 
way to prevent or delay craniosynostosis progression. 
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Introduction 
Normal craniofacial development is a precisely coordinated process that involves the modelling of a 
framework supporting the soft tissues of the head, in particular the brain. During normal development, 
growth of the brain is possible because suture tissue separates the calvarial bones and allows for skull 
vault expansion. Craniosynostosis, a common birth defect with an incidence of 1:2,500, is 
characterised by the loss of suture tissue followed by premature fusion of calvarial bones. This results 
in the restriction of brain growth and is often associated with dramatic dysmorphology of the skull 
and face. A significant number of craniosynostosis cases are syndromic and associated with additional 
skeletal phenotypic features. Many of these syndromes are caused by mutations in FGF pathway 
genes (Johnson and Wilkie, 2011).  
FGF signalling is important for cellular proliferation, differentiation and survival. Receptor activation 
allows signals to be conveyed through the RAS-MAPK, P13K-AKT and PLCγ-PKC cascades via a 
series of protein intermediates (Ornitz and Itoh, 2015, Eswarakumar et al., 2005). FGF receptors 
(FGFRs) are highly conserved receptor tyrosine kinases (RTKs) located on the cell membrane with 
intracellular and extracellular domains. Tissue specific isoforms are produced by alternative splicing, 
affecting the third extracellular immunoglobulin-like loop (DIII) of FGFR1-3. The FGFR ‘IIIb’ and 
‘IIIc’ isoforms differ only in the C-terminal half of DIII, which is encoded by exons 8 or 9 for the IIIb 
and IIIc splice forms respectively (Eswarakumar et al., 2005, Ornitz and Itoh, 2015). Furthermore, the 
expression of the isoforms are tissue specific and critical for establishing paracrine reciprocal 
signalling loops: while the IIIb isoform is commonly expressed in epithelial cells and receives FGF 
ligand from the mesenchyme, the IIIc is expressed in mesenchymal cells and receives FGF ligand 
from the neighbouring epithelium (Orr-Urtreger et al., 1993). 
Mutations affecting the FGFR2 gene can cause a spectrum of craniofacial phenotypes commonly 
associated with growth dysplasia, mid-facial hypoplasia, coronal synostosis, orbit dysmorphology and 
cleft palate (Wilkie, 1997). Notably, synostosis of the coronal suture is a hallmark for human 
Crouzon-Pfeiffer syndromes (CPS) (Johnson and Wilkie, 2011). Crouzon syndrome is most 
commonly caused by a point mutation in exon 9 of the FGFR2 gene, is autosomal dominantly 
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inherited and exclusively affects the IIIc isoform (Reardon et al., 1994). The substitution of a cysteine 
to a tyrosine residue (p.C342Y) results in the stabilization of intermolecular disulphide bonds in the 
receptor extracellular domains that lead towards ligand independent receptor activation and is often 
referred to as a gain-of-function (GOF) mutation (Reardon et al., 1994). 
In the developing mouse cranial vault, Fgfr2 is expressed in the osteogenic fronts of the calvarial 
bones, but the specific cellular localisation of the different Fgfr2 isoforms remains elusive due to their 
high sequence homology (Johnson et al., 2000, Iseki et al., 1997). FGFR2c function is commonly 
associated with craniofacial and skeletal development as genetic mutation in mouse models leads to a 
series of craniofacial malformations and additional skeletal dysmorphology (Lee et al.). Deletion of 
the FGFR2c isoform (Fgfr2cnull) results in skeletal hypoplasia and craniosynostosis due to imbalances 
in osteoprogenitor proliferation and differentiation in the endochondral as well as the 
intramembranous skeleton (Eswarakumar et al., 2002). The most common coding mutation 
responsible for human Crouzon syndrome has been introduced into the mouse (Fgfr2cC342Y) to study 
the pathogenesis of the disease in more detail (Eswarakumar et al., 2004). The craniofacial phenotype 
in these mice includes brachycephaly due to postnatal coronal craniosynostosis, as well as a short 
snout caused by midfacial hypoplasia (Eswarakumar et al., 2004). Contrary to Fgfr2cnull mice, 
increased numbers of osteoprogenitor cells were observed, but paradoxically, synostosis of the 
coronal suture was also present (Eswarakumar et al., 2004). Recently, it was shown that increased 
levels of MAPK/ERK signalling downstream of FGFR2c are present in suture osteoprogenitors in 
Fgfr2cC342Y but not Fgfr2cnull mice (Pfaff et al., 2016). In addition, hemizygous mutants (Fgfr2cC342Y/-) 
show a more severe craniofacial phenotype, demonstrating that lowering the Fgfr2c expression levels 
does not alleviate the features associated with FGFR2c activation (Pfaff et al., 2016). Altogether, the 
mechanism behind pathogenic FGFR2c signalling in the coronal suture is complex as indicated by the 
observation that coronal synostosis is a notable phenotype to both activation (Fgfr2cC342Y) and loss 
(Fgfr2cnull) of FGFR2 signalling (Eswarakumar et al., 2002, Eswarakumar et al., 2004). Furthermore, 
analysis of the cleft palate phenotype in Fgfr2cC342Y mice demonstrates that activation as well as 
inhibition of FGF receptor signalling causes delayed palatal shelf growth and elevation (Snyder-
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Warwick et al., 2010). These results imply that the downstream interpretation of FGFR2c signalling 
can be different to the activity of the receptor itself, and the phenotype elicited may not be a direct 
translation of an overactive FGFR2c signalling pathway. 
The complexities of FGFR2c signalling prompted us to delineate the molecular basis for signalling 
misregulation further by studying Fgfr2c receptor overexpression using a conditional allele that 
allows tissue-specific induction (i.e. R26RFgfr2c-flox). This study reports that the phenotypic 
consequences of Fgfr2c overexpression show similarities as well as differences to those found in 
Fgfr2cC342Y and Fgfr2cnull mice. We have interrogated the biochemical and transcriptional FGFR2 
pathway activity in the coronal sutures prior to the onset of synostosis, and show that both constitutive 
activation and overexpression of FGFR2c results in increased levels of ERK phosphorylation in vivo. 
Furthermore, we provide evidence that increasing the expression of a wild-type Fgfr2c allele can 
ameliorate the craniosynostosis phenotype in Fgfr2cC342Y Crouzon mice. 
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Results 
Fgfr2c overexpression causes growth restriction, microtia and cleft palate. 
To assess which tissues are sensitive to increased FGFR2c signalling, R26RFgfr2c-flox mice were crossed 
with βactinCRE mice to drive ubiquitous Fgfr2c overexpression (Figure 1A). Ubiquitous 
overexpression of the R26RFgfr2c allele (i.e. R26RFgfr2c-flox; βactinCRE abbreviated to R26RFgfr2c;act) led to 
a total upregulation of Fgfr2c transcripts close to 2-fold (n=3) as shown by qPCR (Supplementary 
Figure 1A) at E12.5. Transgenic FGFR2c-V5 protein expression was validated at E12.5 by 
immunoblotting showing transgenic protein in the CRE positive animals only (Supplementary 
Figure 1B). Subsequently, R26RFgfr2c;act embryos were examined at E18.5 for their size (Head Length 
and Crown Rump Length (CRL)) and weight (Figure 1C, D and E). Results were expressed as an 
average percentage change (Av.Δ %) relative to controls (R26RFgfr2c-flox). Ubiquitous Fgfr2c 
overexpression (n=9) led to a significant reduction in the head length (Av.Δ 7.19%; p<0.0001; 
t(17.78)=7.74), CRL (Av.Δ 4.83%; p=0.0018; t(13.23)=3.90) and weight (Av.Δ 12.26%; p=0.0001; 
t(22.16)=5.39) to controls (R26RFgfr2c-flox; n=17) (Figure 1C, D and E). Additionally, R26RFgfr2c;act 
mice display microtia characterised by a smaller or absent pinna (n=6/6) (Figure 1B). To assess 
whether decreased size was due to generalised defects of the whole skeleton we analysed limb length 
as a proxy for this (Supplementary Figure 2). No difference in the size of the limbs (n=13) was 
detected, suggesting that the overall size reduction was mostly due to reduced head size. Whole 
mount skeletal staining of the head showed that mutants had craniofacial dysmorphology showing 
notable disruptions to the tympanic ring of the middle ear (n=9/10) and a cleft palate (n=4/10) 
(Figure 2A). As different parts of the calvaria are derived from either the neural crest or mesodermal 
lineage (Yoshida et al., 2008), R26RFgfr2c-flox animals were subsequently crossed with Wnt1CRE or 
Mesp1CRE to ask which cell types are responsible for the observed phenotypes, and to eliminate any 
potential ectopic effects generated by the ubiquitous βactinCRE line. To assess the promoter activity of 
the different CRE lines specifically in calvarial tissues we investigated conditional fluorescent alleles 
(i.e. mTmG and YFP). We found that expression was robust and specific for all CRE lines 
(Supplementary Figure 3). R26RFgfr2c;Wnt1 embryos (n=6) showed a significant decrease in weight 
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(Δ12.26%; p=0.0028; t(9.23)=4.05) while head length and CRL were not significantly reduced 
(Figure 1C, D and E). Moreover, the clefting phenotype was heterogeneous in its severity: 1 out of 6 
embryos exhibit an overt cleft whilst 3 out of 6 display palatal shelf hypoplasia (data not shown) 
(Figure 2A). In contrast to R26RFgfr2c;act mice, middle (tympanic ring) or outer (pinna) ear defects 
were absent in this cohort of embryos (n=0/6) (Figure 2A). In R26RFgfr2c;Mesp1, no defects were present 
in the ear or the palate (n=0/9) (Figure 2A) and no significant effects on size were seen in embryos 
upon Fgfr2c overexpression in the mesoderm using Mesp1CRE (n=9) compared to controls (n=4) 
(Figure 1C, D and E). Together, ubiquitous and conditional Fgfr2c overexpression in the neural crest 
lineage stunts overall growth resembling the phenotypic effect of Fgfr2cnull knockout mice. 
Additionally, Fgfr2c overexpression mutants display microtia and cleft palate, of which the latter is 
also found in Fgfr2cC342Y mutants, but has not been identified in Fgfr2cnull mice. 
Fgfr2c overexpression causes anterior, neural crest derived bone hypoplasia. 
As all observed phenotypic features in R26RFgfr2c mice seem to affect tissues in the head, we assessed 
the craniofacial morphology in more detail at E18.5 using Alcian Blue/Alizarin Red whole-mount 
skeletal staining and quantified the size and shape of individual craniofacial bones. The results were 
expressed as an average percentage change in the mutants relative to the controls (R26RFgfr2c-floxed) 
normalised to 100% (Av.Δ %). Frontal bones of R26RFgfr2c;act skulls were significantly smaller 
(Av.Δ11.4%; p<.0001; t(22.98)=6.99; n=9) (Figure 2B and C) along with other neural crest 
derivatives such as nasal bone (Av.Δ 12.90%; p<0.0001; t(22.06)=7.91; n=10) and mandible (Av.Δ 
5.77%; p<0.0001; t(20.64)=7.30; n=9) (Supplementary Figure 4). No significant reduction was 
observed in the mesoderm-derived parietal bone. Similarly, R26RFgfr2c;Wnt1 embryos followed a 
comparable trend with significant decreases in neural crest derivatives: frontal bone (Av Δ9.12%; 
p=.0131; t(6.89)=3.32; n=6), nasal bone (Av.Δ 7.91%; p=.0024; t(9.077)=4.17; n=6); and mandible 
(Av.Δ3.71%) (p=.0007; t(9.96)=4.82; n=6). Again, no size difference was seen in the 
mesoderm-derived parietal bone (n=6). As expected, in R26RFgfr2c;Mesp1 mice, calvarial bone sizes were 
not affected. In summary, Fgfr2c overexpression causes bone hypoplasia of anterior, neural crest 
derived bones, explaining the overall reduction of craniofacial dimensions. 
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Fgfr2c overexpression does not cause coronal craniosynostosis. 
Coronal synostosis is a hallmark of Crouzon-Pfeiffer syndrome and can be observed in the 
Fgfr2cC342Y mouse model as well as the Fgfr2cnull mice. While subtle changes in the Fgfr2cC342Y 
heterozygous coronal suture morphology are visible from E17.5, full fusion of frontal and parietal 
bones is not visible until three weeks after birth. Due to the presence of a cleft palate in R26RFgfr2c;act 
embryos, mice do not survive after birth, making it impossible to assess the postnatal synostosis 
phenotype. Ex vivo explant cultures were adopted to overcome this problem. Calvarial explant 
cultures in our laboratory routinely show that coronal synostosis can be achieved in vitro after 1-2 
weeks of culture in Fgfr2cC342Y heterozygote E17.5 explants. In R26RFgfr2c;act calvaria, coronal 
synostosis was not observed (n=6), similar to wild-type and R26RFgfr2c-floxed controls (n=7). At the 
same time, Fgfr2cC342Y heterozygous coronal sutures are reduced in size and signs of suture fusion can 
be observed after 15 days in culture (Figure 3). Additionally, we have examined the effect of FGFR2 
perturbation on osteoblast maturation at a pre-synostosis embryonic stage (E16.5) by analysing 
alkaline phosphatase (ALP) activity. In all cases, Fgfr2cC342Y heterozygous sutures display increased 
suture overlap and ectopic ALP in the sutural mesenchyme (n=3) whilst R26RFgfr2c;act frontal and 
parietal bones are spaced normally and resemble controls (n=3) (Figure 4). This data implies that 
FGFR2c overexpression does not cause coronal craniosynostosis and does not mimic FGFR2 
activation in the Fgfr2cC342Y suture. 
FGFR2c overexpression and FGFR2c-C342Y mutation activate MAPK/ERK signalling in the 
suture. 
To assess whether Fgfr2c overexpression leads to a similar activation of the MAPK/ERK pathway as 
found in the Fgfr2cC342Y mouse, we looked at levels of pERK in the suture in vivo and in vitro. We 
sought to visualise the expression of pERK in E16.5 coronal sutures using immunohistochemistry at a 
stage where the sutures were morphologically similar, i.e. prior to the onset of synostosis 
(R26RFgfr2c;act, n=3; Fgfr2cC342Y/+, n=4; control, n=4). Interestingly, both Fgfr2cC342Y/+ and 
R26RFgfr2c;act mutants showed upregulated pERK in the osteogenic fronts of frontal and parietal bones 
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flanking the suture (Figure 5A). We have also modelled pERK activity in vitro using the human 
embryonic kidney (HEK293T) cell line (n=4 independent transfections). pERK 1 and 2 were activated 
upon transfection of pFGFR2c(WT)V5 (encoding the wild-type FGFR2-IIIc isoform) and 
pFGFR2c(C342Y)V5 (encoding the mutated receptor) relative to mock transfected cells (Figure 5B). 
Quantification of the blots using densitometry reveals significant upregulation of pERK in both 
FGFR2cV5 transfected conditions (Figure 5C). Specifically, there was significantly more pERK 
activity in the C342Y-V5 (p<0.0001) and WT-V5 (p=0.0101) transfected cells relative to the 
pcDNA3.1 control cells as expected from the Western blot results. Cells transfected with C342Y-V5 
has an increased pERK output by 8.1 units than that of WT-V5 transfected group (p=0.0005) likely 
due to the constitutive activation of the mutant receptor. While both models show an activated RAS-
MAPK pathway in the suture, the fact that only Fgfr2cC342Y activation results in craniosynostosis 
suggest that FGFR2c overexpression cascade activation is functionally distinct to that of the mutant 
receptor. 
Introduction of the Fgfr2c overexpression allele into Fgfr2cC342Y mice delays craniosynostosis. 
As FGFR2c overexpression does not cause coronal suture synostosis, we hypothesized whether the 
addition of this allele to the Fgfr2cC342Y mice would modify the craniofacial phenotype. To assess the 
impact of the overexpression allele, we have generated a double mutant (i.e. R26RFgfr2c;act 
;Fgfr2cC342Y) and performed quantitative analysis on the calvaria as before (Figure 6). The most 
apparent external anomaly resulting from Fgfr2c overexpression alone was microtia. This was 
exacerbated in double mutants where anotia was present in 90% of mice (Figure 6A) (n=10/11). 
External ear development was normal in all Fgfr2cC324Y single mutants (n=15). Double mutants 
showed cleft palate with an increased penetrance (n=7/7). Examination of the craniofacial skeleton 
reveals partial rescue of the Crouzon phenotype: an ectopic interfrontal Wormian bone is 
characteristic of Fgfr2cC342Y heterozygotes (n=6/7), and these were generally smaller in double 
mutants (n=4/5) combined with an enlarged widening of the posterior interfrontal suture (Figure 6B). 
In general, quantitative analyses of calvarial bones show that R26RFgfr2c;act ;Fgfr2cC342Y frontal bones 
were smaller than those of controls (Av.Δ11.86; p<0.001; control: n=8, double mutant: n=6) (Figure 
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6C). Significance size reduction was present when R26RFgfr2c;act frontal bones (n=6) were compared to 
Fgfr2cC342Y (n=10)(Av.Δ 9.19%; p=0.001). Also, there was a significant decrease in frontal bone size 
between R26RFgfr2c;act ;Fgfr2cC342Y and Fgfr2cC342Y (Av.Δ 14.80%; p<0.001). Quantitative analysis of 
the parietal bones indicates significant increase in the parietal bone of Fgfr2cC342Y (n=10) as compared 
to all other genotypes (control: Av.Δ6.54%, p=0.001, n=8; R26RFgfr2c;act Av.Δ6.08%, p=0.006, n=6; 
R26RFgfr2c;act ;Fgfr2cC342Y: Av.Δ5.44%, p=0.016, n=6) (Figure 6D). Most strikingly, coronal sutures 
in double mutants appeared more patent than those in Fgfr2cC342Y alone. Frontal and parietal bone 
overlap was decreased in R26RFgfr2c;act ;Fgfr2cC342Y coronal sutures shown by Alizarin Red stain and 
ALP activity (Figure 6B) (control: n=2; Fgfr2cC342Y: n=2; R26RFgfr2c;act ;Fgfr2cC342Y: n=3). However, 
the observed ectopic ALP in the sutural mesenchyme of Fgfr2cC342Y animals (see Figure 4) was not 
decreased in the majority of double mutant sutures (Figure 6B). This suggests that the overexpression 
allele is potentially only delaying the synostosis process, possibly through calvarial bone hypoplasia 
caused by decreased osteogenic differentiation or increased mesenchymal proliferation. 
Increased proliferation in R26RFgfr2c;act ;Fgfr2cC342Y double mutants. 
To test the hypothesis that altered proliferation in the suture underlies the delayed onset of 
craniosynstosis in R26RFgfr2c;act ;Fgfr2cC342Y double mutants, we performed phoshohistone-3 (PHH3) 
immunohistochemistry to assess mitotic index (Figure 7A). While levels of proliferation were 
unchanged in the periosteum overlying the coronal suture, a statistically significant (P<0.05) increase 
was detected in the sutural mesenchyme of double mutants compared to Fgfr2cC342Y mutants alone 
(Figure 7B). This implies that the addition of the R26RFgfr2c;act allele increases sutural proliferation, 
which in turn delays osteogenic differentiation. This leads to bone hypoplasia and rescues the 
craniosynostosis phenotype. 
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Discussion 
The paradox of FGFR2c signalling was first implicated when it was found that craniosynostosis can 
be caused by deletion of the IIIc isoform (Fgfr2cnull), as well as by introducing an activating mutation 
linked to human Crouzon syndrome (Fgfr2cC342Y) (Eswarakumar et al., 2002, Eswarakumar et al., 
2004). Fgfr2cC342Y heterozygotes display an early postnatal craniosynostosis phenotype where 
Fgfr2cnull mice show late postnatal onset (Eswarakumar et al., 2004, Eswarakumar et al., 2002). We 
sought to increase our understanding of FGFR2c signalling misregulation through Fgfr2c 
overexpression and comparison to Fgfr2cC342Y. Our data shows that global Fgfr2c overexpression 
yields craniofacial hypoplasia, microtia and cleft palate. Strikingly, this cohort of mutants did not 
develop coronal synostosis as opposed to Fgfr2cC342Y and Fgfr2cnull mutants. 
There are no reports of external ear defects related to human Crouzon syndrome or in 
Fgfr2cC342Ymice. This study describes microtia with hypoplasia of the tympanic ring in R26RFgfr2c;act 
that has similarities to lacrimo-auriculo-dento-digital (LADD) syndrome which can be caused by 
mutations in FGF10 or FGFR2 (Rohmann et al., 2006). However, the external ear phenotype 
observed in the R26RFgfr2c;act is more likely to be a consequence of ectopic expression of FGFR2c in 
the ectoderm, potentially activated in an autocrine way by ectodermal FGF ligands with a high 
affinity for the IIIc isoform (Wright and Mansour, 2003). The lack of an external ear phenotype 
observed in other mouse models of Fgfr2c supports this (Eswarakumar et al., 2002, Eswarakumar et 
al., 2004). Nonetheless, a clear hypoplastic tympanic ring was noted in R26RFgfr2c;act mutants, a 
phenotype similar to Fgfr2cnull embryos at E18.5, implying the importance of FGFR2c in the 
osteogenesis of the auditory bulla (Eswarakumar et al., 2002).   
Murine palatogenesis commence at E11.5 and is complete by E17.5 (Bush and Jiang, 2012). The 
prevalence of cleft palate in human Crouzon syndrome is less than that in Apert patients, which may 
be due to the mutation affecting both isoforms in the latter (Stanier and Pauws, 2012). The overt cleft 
phenotype in both R26RFgfr2c;act and R26RFgfr2c;Wnt1 was not fully penetrant: 40% (4/10) of R26RFgfr2c;act 
embryos and 16% (1/6) for R26RFgfr2c;Wnt1 respectively. As Fgfr2b is a major player for palatal shelf 
elevation, the partial penetrance implicates the IIIc isoform is less critical to this process, which is 
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supported by the observation that Fgfr2cnull mice do not have a cleft palate phenotype (Rice et al., 
2004, Eswarakumar et al., 2002). However in the double mutants (i.e. R26RFgfr2c;act ; Fgfr2cC342Y) the 
penetrance of cleft palate was 100% (n=7/7), indicating that the combination of the constitutively 
active receptor in with Fgfr2c overexpression exacerbates the cleft phenotype, resembling the 
Fgfr2cC342Y homozygotes (Peskett et al., 2017).  
Our data supports the conclusion that craniofacial hypoplasia is likely to be a result of conditional 
Fgfr2c overexpression in the neural crest (NC) lineage. A previous quantitative analysis of the adult 
Fgfr2cC342Y reports smaller frontal and nasal bones, accompanied by a short anterior cranial base (Liu 
et al., 2013). Diminished calvarial bone volume was also reported in other mouse models for 
syndromic craniosynostosis most notably in Fgfr2S252W and Fgfr3P244R (Muenke syndrome) (Twigg et 
al., 2009, Chen et al., 2003). This is consistent with our finding that hypoplasia of NC derived bones 
is present in E18.5 R26RFgfr2c;act mice. Instead of a specific effect on NC derived tissues, it is also 
possible that ectopic expression of FGFR2c in the R26RFgfr2c;act mice plays a role. As mentioned 
before, expression of FGFR2 in the ectoderm is the likely explanation for the microtia phenotype. 
Similarly, ectopic expression in any other non-NC cells, or increased expression of FGFR2 in NC and 
mesoderm concomitantly during embryonic development of the head may contribute to the different 
craniofacial phenotype found in R26RFgfr2c;act mice compared to R26RFgfr2c;Wnt1  and R26RFgfr2c;Mesp1 
mice. Interestingly, Fgfr2cC342Y embryos at E18.5 do not show similar signs of hypoplasia at this 
stage. This is likely due to the nature of the C342Y mutation, which plays different roles in both early 
and late stages of development (Liu et al., 2013, Mansukhani et al., 2000). The C342Y mutation 
favours premature osteoblast commitment but inhibits bone mineralisation and facilitates cellular 
apoptosis during late gestation (Liu et al., 2013, Mansukhani et al., 2000, Rice et al., 1999). Despite 
similarities observed in the anterior bone phenotype of Fgfr2cC342Y and R26RFgfr2c;act, it is likely that 
the mechanism behind the phenotype is different. We propose that the hypoplasia found in 
R26RFgfr2c;act mutants is mainly a result of insufficient osteogenesis but we cannot exclude an ectopic 
effect at this stage.  
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A major difference between the R26RFgfr2c;act mice and Fgfr2cC342Y mutants is the absence of coronal 
synostosis in the overexpression model. Neither do R26RFgfr2c;act mutants mimic the coronal 
synostosis phenotype of Fgfr2cnull mice. It is likely that the overall signalling disruption by receptor 
overexpression is less extreme than that of complete signalling removal (Fgfr2cnull) or a constitutively 
active receptor (Fgfr2cC342Y). This is reflected by the relatively subtle phenotypic spectrum even with 
ubiquitous receptor overexpression under the control of the βactin promoter (R26RFgfr2c;act). 
MAPK/ERK signalling is confined within a specific spatial domain along the membranous bones and 
the osteogenic fronts of the coronal suture. This was expected as the expression of Spry downstream 
targets coincides with periosteoblast cells known to be expressing Fgfr2 (Deckelbaum et al., 2005, 
Johnson et al., 2000). Also, the relevant FGF ligands are confined to the osteogenic front. For 
example, Fgf18 and Fgf20 transcripts were detected in the osteogenic fronts of the coronal suture, 
coinciding with those genes involved in FGFR2 signalling, pointing towards potential autocrine 
interactions (Hajihosseini and Heath, 2002, Ornitz and Itoh, 2015).  However, owing to the nature of 
ubiquitous overexpression and the morphogenic nature of FGFs, we expected ectopic expression to 
affect the R26RFgfr2c;act suture mesenchyme. The lack of phenotype in these overexpressing mutants 
suggests that while pERK is upregulated in both Fgfr2cC342Y and R26RFgfr2c;act, only Fgfr2cC342Y 
sutures show increased differentiation as shown by increased levels of alkaline phosphatase, hence the 
craniosynostosis phenotype. Together this suggest that augmentation of MAPK/ERK signalling in the 
suture alone is not sufficient to derive a coronal synostosis phenotype in the craniofacial skeleton 
(Eswarakumar et al., 2004, Pfaff et al., 2016, Li et al., 2007). 
Phenotypic rescue of the coronal suture could be generally achieved at the level of the receptor such 
as uncoupling Frs2 or through ERK knockdown (Eswarakumar et al., 2006, Shukla et al., 2007). 
Ultimately, the aim is to ameliorate Crouzon phenotype through FGFR2c signalling attenuation. We 
sought to address whether Fgfr2c overexpression is sufficient to delay ossification in Fgfr2cC342Y 
given by the biochemical properties reported in vitro (Miraoui et al., 2009, Baddoo et al., 2003). 
Previous studies attempted to elucidate the paradoxical nature of FGFR2 signalling, where the 
perception of a GOF mutation leads towards signalling activity attenuation (Snyder-Warwick et al., 
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2010, Pfaff et al., 2016, Bagheri-Fam et al., 2015). Specifically, two studies attempted to ameliorate 
phenotypes caused by the C342Y allele, by introducing the C342Y allele into the Fgfr2cnull 
background but yielded a more severe phenotypic spectrum (Pfaff et al., 2016, Bagheri-Fam et al., 
2015). Our data suggests that the Fgfr2c overexpression allele was sufficient to delay synostosis. In 
particular, the extent of suture overlap in R26RFgfr2c;act ; Fgfr2cC342Y mutants was decreased compared 
to control or Fgfr2cC342Y mice. However, suture abolishment remains apparent due to the presence of 
the Fgfr2cC342Y allele. As FGFR2 is critical for cell-renewal, one speculation for this rescue is shifting 
the balance from osteoblast differentiation to proliferation through ‘scavenging activity’ of 
endogenous FGF ligands by excess FGFR2c. Our results show that there is a distinct increase of 
proliferation in the sutural mesenchyme of R26RFgfr2c;act ; Fgfr2cC342Y double mutants which would 
indicate a shift from differentiation to proliferation, explaining the osteogenic hypoplasia and the 
absence of craniosynostosis. This hypothesis is also supported by in vitro culture experiments with 
MSCs, as exposure to FGF2 promotes stemness in the presence of osteoblast differentiation media 
(Baddoo et al., 2003). Another possibility is that the addition of an extra wild-type Fgfr2c allele into 
the Fgfr2cC342Y heterozygous mice disrupts the receptor turnover at the membrane and/or disturbs the 
dimerization equilibrium, favouring WT homodimers over WT/C342Y heterodimers. Altogether, the 
delayed synostosis in double mutants suggests Fgfr2c overexpression partially rescues reduced 
premature osteoblast commitment caused by the C342Y allele (Eswarakumar et al., 2004, Peskett et 
al., 2017).  
We propose the FGFR2c paradox should not be based solely on the signalling amplitude but rather, 
the cascade FGFR2c transactivates. This is due to activation of TRK receptors, such as FGFR2, 
triggers signal transduction through three major cascades (PI3K-AKT, RAS-MAPK and PLCγ-PKC) 
(Ornitz and Itoh, 2015). It was previously reported that GOF mutations in the FGFR2c receptor elicit 
dissimilar cascade activation to that of WT-FGFR2c (Kim et al., 2003, Miraoui et al., 2009). Miraoui 
et al., 2009 compared the differences in cascade activation and concluded that Apert-FGFR2-S252W 
transactivates the PLCγ-PKC pathway to drive osteoblast differentiation and mineralisation, whereas 
WT-FGFR2 predominantly signals through the RAS-MAPK pathway (Miraoui et al., 2009). Other 
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growth factor pathways involving TRK receptors misregulation behave similarly, for example 
PDGFRα, where sustained activation of the receptor is responsible for complex craniosynostosis 
through PLCγ-PKC cascade (Moenning et al., 2009). Generally speaking, augmentation of 
RAS-MAPK signalling promotes proliferation whilst cellular differentiation is a consequence of 
cascade suppression (Dinsmore and Soriano, 2018). This cellular consequence is comparable to 
embryonic stem cells maintaining pluripotency (Yamanaka et al., 2010). For example, in the murine 
palate, it is understood that proliferation of palatal mesenchyme cells are driven by activated ERK 
through the exposure to FGFs in culture, and that its inhibition led to downregulation of ‘stemness’ 
genes (Vasudevan et al., 2015). In the same study, genetic ablation of Fgfr1 (Fgfr1null) led to ectopic 
osteoblast differentiation in the palatal shelves in vivo (Vasudevan et al., 2015). Unpublished data 
from this laboratory also supports this as oncogenic activation of KRas (i.e. KRas-G12D), an effector 
of the MAPK/ERK pathway in the NC lineage (KrasG12D;Wnt1) led to severe craniofacial hypoplasia. 
Oncogenic KRas is known to cause terminal differentiation defects, suggesting upregulation of 
MAPK/ERK signalling alone resulted in insufficient osteoblast differentiation (Tuveson et al., 2004, 
Haston et al., 2017). Therefore, the pathogenic mechanism for craniosynostosis cannot be attributed to 
RAS/MAPK misregulation alone. 
In summary, this study has demonstrated that FGFR2c overexpression yields craniofacial hypoplasia 
without a craniosynostosis phenotype. The most striking observation is the phenotypic variation 
between R26RFgfr2c;act and Fgfr2cC342Y despite similarities in signalling dynamics. This implies that 
receptor overexpression and GOF mutations are mechanistically different, and require a different 
downstream interpretation to the WT. This is well characterised in vitro with preferential signal 
transduction, and our results relate these findings to an in vivo context. Maintaining the correct 
balance between proliferation and differentiation is crucial for osteogenesis and suture patency. 
Elucidating the role of FGFR2c signalling will improve the understanding of normal craniofacial 
development and its related pathologies, while providing a framework for the development of novel 
therapeutic strategies. 
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Materials and methods 
Animals 
Fgfr2c overexpression mouse (Gt(ROSA)26Sortm1(Fgfr2-IIIc)Pauw; aka R26RFgfr2c-flox; MGI:6150825). To 
target the Rosa26 genomic locus (Gt(ROSA)26tm1Sor), an Fgfr2c cDNA expression construct 
containing a V5 epitope on the C-terminal end of the protein was inserted into a targeting vector 
carrying the loxP-PGK-neo-tPa-loxP cassette (Soriano 1999), followed by homologous recombination 
and the creation of chimera. Germline mice carrying the R26RFgfr2c-flox allele were backcrossed onto a 
CD1 background and maintained as homozygotes. To generate Fgfr2c overexpressing mutants, mice 
carrying the R26RFgfr2c-flox allele were crossed with animals carrying a Cre recombinase allele 
(βactinCRE; Wnt1CRE or Mesp1CRE). Embryos were genotyped for Cre recombinase and loxP excision. 
Genotyping primers are available upon request. 
Crouzon mouse model (Fgfr2tm4Lni; aka Fgfr2cC342Y; MGI:3053095). Fgfr2cC342Y were re-derived 
through the European Mouse Mutant Archive (EMMA) at MRC Harwell as previously described 
(Peskett et al., 2017). 
Generation of double mutants was performed by crossing R26RFgfr2c-flox animals with Fgfr2cC342Y 
heterozygotes followed by genotyping for both alleles. Fgfr2cC342Y; R26RFgfr2c-flox animals were 
subsequently crossed with βactinCRE to generate ubiquitous overexpression in the Crouzon mouse (i.e. 
R26RFgfr2c;act ;Fgfr2cC342Y). 
Wnt1CRE;R26RYFP was as previously described (Freem et al., 2010). CRE recombinase is driven under 
the control of the Wnt1 promoter to generate conditional expression in the NCC lineage. Wnt1CRE mice 
were crossed with R26RYFP/YFP reporter to generate Wnt1CRE/+; R26RYFP/+ offspring. Cells positive with 
the CRE allele will express the reporter protein, thus labeling cells from the NCCs lineage. 
R26RmTmG/mTmG were as previously described (Muzumdar et al., 2007). The mTmG allele was crossed 
with R26RFgfr2cV5/Fgfr2cV5 to generate a double conditional mouse that overexpresses both mTmG and 
Fgfr2cV5 (R26RmTmG/+; R26RFgfr2cV5/+) upon CRE deletion. 
All animal procedures were performed in accordance with the UK Animals (Scientific Procedures) 
Act 1986 (Project License number: 70/8817) and maintained by UCL Biological Services. 
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Cells 
Human embryonic kidney (HEK293T) cells were cultured in Minimum Essential Medium (MEM) 
alpha culture medium (Thermo Fisher Scientific) supplemented with 10% Fetal Bovine Serum (FBS) 
and Penicillin-Streptomycin. Cells were transfected with pcDNA3.1 (Invitrogen) plasmids containing 
a FGFR2c ORF (wild-type (WT) and C342Y) with a V5 tag on the C-terminal end, as well as control 
pcDNA3.1 without insert when they had reached 50% confluence. A cocktail of Optimem culture 
medium (Gibco), FuGENE transfection reagent (Promega) and plasmid DNA was added to each well 
prior to 48 hours incubation at 37°C, 5% CO2. 
Immunoblots 
E12.5 embryos were dissected under ice cold PBS and homogenized in RIPA buffer (150mM NaCl, 
1% Triton X-100 (Fisher), 0.5% sodium deoxycholate (Sigma), 0.1% SDS (Sigma), 50mM Tris-pH 
8.0 (Fisher)) with MINI complete protease inhibitor cocktail (Sigma) and centrifuged to obtain the 
lysates. Protein concentration was determined using Bradford reagent (Biorad) and 
spectrophotometry. A special cell lysis buffer (50mM pH7.6 Tris-Base; 150mM NaCl, 1% Triton X-
100, 0.02% Sodium Azide, 1mM MINI protease inhibitor (Roche), 1mM sodium orthovanadate, 
25mM sodium fluoride) was adopted for cells. Lysates were resolved, transferred and blotted using 
standard protocols. Anti-V5 antibody (Invitrogen) was used at a concentration of 1:1000 for E12.5 
embryos and 1:3000 for cell lysates. Anti-pERK (1:2000, Cell Signalling Technology) and anti-tERK 
(1:2000, Cell Signalling Technology) were used to determine pathway activity. pERK blots were 
quantified by densitometry using FIJI software, and results expressed as the relative pERK:tERK 
ratio. 
Quantitative RT-qPCR 
RNA was extracted using the Trizol method (Invitrogen). Any genomic DNA was subsequently 
eliminated using the DNA-free DNA Removal Kit (Ambion) prior to RT reaction. QuantiTect 
Reverse Transcription Kit (Qiagen) was used for cDNA synthesis. cDNA was used for RT-qPCR 
reactions using Taqman assays (Applied Biosystems) according to the manufacturer’s protocol. 
Fgfr2c assay (Applied Biosystems; Mm01269938_m1) was used to determine Fgfr2c overexpression. 
The collected dataset was analysed using the 7500 Fast Real-Time PCR System (Applied 
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Biosystems). Amplification efficiencies were checked for target genes and controls prior to data 
analysis using the ΔΔCt method.  
Ex vivo calvarial explants 
A calvarial explant protocol was performed as previously described (Lana-Elola et al., 2007). 
Embryos were harvested at E17.5 and dissected in PBS. The calvaria was removed from the skin and 
brain and cultured in Dulbecco’s Modified Eagle Medium (DMEM, Sigma) supplemented with 10% 
Fetal Bovine Serum (FBS, Sigma) and Penicillin-Streptomycin. The medium, with or without the 
addition of 10ng/ml FGF2, was refreshed every other day and cultured for 10-15 days at 37oC, 5% 
CO2. Calvaria were fixed in 90% ethanol and processed for Alizarin Red staining. 
Gross phenotypic analysis 
Embryos were weighed using a fine balance. An electronic caliper (Fisher) was used to measure the 
crown-rump length and head length of the embryo.  
Wholemount skeletal staining 
The procedure for wholemount skeleton histology was as previously described (Peskett et al., 2017). 
E18.5 embryos were skinned, eviscerated and fixed in 90% EtOH overnight at 4oC and stained with 
Alcian Blue (Sigma) working reagent (0.01% Alcian Blue; 20% Acetic Acid; 80% of 75% EtOH) 
overnight at RT.  Embryos were washed in 75% EtOH for a further 24 hours and cleared in 1% 
Potassium Hydroxide (KOH) the following day. After sufficient clearing, 0.01% Alizarin Red 
(Sigma) working solution (0.01% Alizarin Red in 1% KOH) was added to the embryos. The embryos 
were stained overnight and washed in 1% KOH the following day. Graded glycerol (Sigma) was used 
to prepare samples for imaging and long-term storage in 80% glycerol.  
Quantitative analysis of the calvaria 
Stained E18.5 calvaria were subjected to ‘Region of Interest’ (ROI) analysis using ImageJ 2.0 
software (NIH). The craniofacial skeleton was dissected for the frontal, parietal and nasal bones in 
80% glycerol and flat mounted onto frosted slides (Fisher). Images were taken for surface area 
measurements of frontal, parietal and nasal bones using ImageJ. Two measurements were made from 
both hemispheres of the bone, and the results were expressed as an average value. The quantification 
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 
 
was performed blind without knowledge of the embryo’s genotype. The mandibles were quantified in 
the same manner with the length measured instead. Quantified data was normalised to limb length 
which provides an endogenous control that was unaffected by increased FGFR2c signalling 
(Supplementary Figure 2). 
Statistical analysis 
SPSS Statistics 22 (IBM) software was used as the primary statistical package for data analysis. First, 
the data was tested for normality using Shapiro-Wilk test to determine the use of parametric or non-
parametric tests. Independent samples t-test with Welch’s correction was used to compare the 
difference of means between the Control and mutant groups for quantification of gross phenotype and 
craniofacial skeleton. One-way ANOVA with Tukey posthoc or non-parametric Kruskal Wallis with 
Dunn-Bonferroni posthoc test was adopted for analysis of three or more groups. A p-value of <0.05 
was considered significant. The analysed data were plotted using Prism 6.0 software (GraphPad).   
Embryo embedding and histology 
For paraffin embedding, E16.5 embryo heads were skinned and fixed in 10% Formalin overnight 
before graded dehydration in ethanol. Embryos were cleared in analytical grade xylene (Fisher) before 
paraffin wax displacement in a 60oC oven. The samples were embedded and sectioned between 8-
10um on the axial plane using a microtome (Leica). For frozen sections, E16.5 or E18.5 heads were 
embedded in OCT and snapped frozen using -80oC isopentane method. Samples were sectioned 
between 15-20µm on the cryostat (Bright). 
Immunofluorescence 
Paraffin sections were dewaxed in Histoclear (National Diagnostics) before graded EtOH rehydration. 
Antigen retrieval was executed in a decloaking chamber (BioCare Medical) at 110oC for 10 minutes 
in 10mM Sodium Citrate pH6.5 buffer. Sections were permeabilised in 0.1% PBST and blocked in 
10% sheep serum (Sigma) and blocking Buffer (0.15% Glycine, 2mg/ml BSA in 0.1% PBST). 
Primary antibodies were incubated on the sections overnight in 1% sheep serum (Sigma) and blocking 
buffer. pERK (rabbit mIgG, Cell Signalling Technology) was used at 1:200, and appropriate 
secondary antibodies were incubated for an hour the following day. Biotin goat-anti-rabbit Alexa 
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Fluor 488 secondaries (Dako) were used against pERK. The pERK signals were amplified using 
Streptavidin 555 conjugates (Life Technologies) at 1:500. 0.1% Sudan black was applied onto tissue 
sections for 5 minutes to quench any autofluorescence, and rinsed briefly in PBST to relieve any 
excess staining. Lastly, tissue sections were stained in DAPI (Thermo Fisher) at 1:10,000 in PBS 
before coverslipped in Mowiol mounting medium (Sigma). 
 Phospho-Histone-H3 (pHH3) immunofluorescence 
Standard immunofluorescence was performed on E18.5 cryosectioned heads. Briefly, cryosections 
were thawed at RT in a humidified chamber and rehydrated in PBS before fixation in 4% PFA, before 
0.1% PBST permeabilisation and non-specific binding blocked in sheep serum as described above. 
Anti-pHH3 (rabbit polyclonal IgG, Millipore) was incubated overnight at a concentration of 1:100 in 
blocking buffer prior to Alexa Fluor 488 (Invitrogen) secondary antibody detection at a concentration 
of 1:250 against host specie. Further washes in 0.1% PBST was carried out prior to DAPI-PBS nuclei 
staining as described above. Sections were coverslipped in Mowiol mounting medium (Sigma) as 
described above. Quantitation of pHH3 cells was achieved using a macro written for FIJI software. 
Mitotic index is expressed as a percentage of the total pHH3 cells in respect to the total number of 
nuclei. The output is subsequently processed for statistical analysis using SPSS (IBM).               
Alkaline phosphatase assay 
Cryosectioned embryos were thawed and immediately fixed in 4% PFA before permeabilisation in 
0.1% TBST. Samples were equilibrated in NTMT before developing in NBT-BCIP solution. 
Developed samples were counterstained with nuclear fast red (Sigma) and mounted in Mowiol 
mounting media (Sigma).   
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Figures 
 
 
 
Figure 1 Gross phenotype of Fgfr2c overexpression in E18.5 mutants. 
(A) Breeding strategy for conditional Fgfr2c overexpression. (B) Microtia (arrowhead + inset) in 
R26RFgfr2c;act only. (C) Skeletal hypoplasia in R26RFgfr2c;act (p<0.0018) (D) Craniofacial hypoplasia in 
R26RFgfr2c;act (p<0.0001) (E) R26RFgfr2c;act and R26RFgfr2c;Wnt1 display significant reductions in weight 
(p<0.0001 and P<0.0028 respectively). Statistics: Students t-test with Welch’s correction. Scale bar: 
5mm. 
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Figure 2 Craniofacial hypoplasia of the NCC lineage in E18.5 mutants. 
(A) R26RFgfr2c;act and R26RFgfr2c;Wnt1 embryos display reductions of the nasal bones and mandibles 
(white and black arrowheads respectively). Other features include an overt cleft palate (asterisk) in 
R26RFgfr2c;act, but only partially penetrant in R26RFgfr2c;Wnt1 embryos. Tympanic ring hypoplasia is 
exclusive to R26RFgfr2c;act embryos (red arrowhead). No apparent phenotype was observed in 
R26RFgfr2c;Mesp1 mice. (B, C) Quantitative analysis of the frontal and parietal bones. Significant 
reductions of the frontal bone in both R26RFgfr2c;act  (p<0.0001) and R26RFgfr2c;Wnt1 embryos 
(p<0.0131). Statstics: Student’s t-test with Welch’s correction. Scale bar: 1mm. 
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Figure 3 Calvarial explant culture of Fgfr2cC342Y and R26RFgfr2c;act mutants. 
Whole calvaria after 10 days in culture show partial fusion in Fgfr2cC342Y heterozygous skulls 
(arrowhead, insert), while in R26RFgfr2c;act calvaria the coronal suture appears patent, resembling the 
control. Calvaria cultured with the addition of FGF2 ligand are undistinguishable from those without 
FGF2. Inserts are a magnified image of the representative coronal suture in the respective explants. 
Scale bar: 1mm. 
  
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
D
M
M
 •
 A
cc
ep
te
d 
m
an
us
cr
ip
t
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Alkaline phosphatase (ALP) activity in the coronal suture. 
Fgfr2cC342Y and R26RFgfr2c;act have dissimilar osteoblast activity in the E16.5 coronal suture. Increased 
appositional growth of Fgfr2cC342Y sutures (arrow) and ectopic expression of ALP in sutural 
mesenchyme precedes synostosis while R26RFgfr2c;act sutures (*) resemble controls. Insert is a 
magnified crop of the suture. F: Frontal bone, P: Parietal bone; Scale bar: 200μm. 
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Figure 5 Fgfr2c overexpression causes upregulation of pERK in vivo and in vitro. 
(A) Both Fgfr2cC342Y and R26RFgfr2c;act mutants have upregulated pERK (red) in osteogenic fronts of 
frontal and parietal bones as compared to controls in vivo. (B) Western blot to demonstrate 
upregulation of pERK upon cellular transfection of pFGFR2c(WT)V5 (encoding the wild-type 
FGFR2-IIIc isoform) and pFGFR2c(C342Y)V5 (encoding the mutated receptor) plasmids in 
HEK293T cells. (C) Relative pERK:tERK ratio quantified by densitometry of transfected HEK293T 
cells. F: Frontal bone; P: Parietal bone; White arrowhead marks the location of the coronal suture. 
Insert is a cropped image of the coronal suture. Statistics: Oneway ANOVA with Tukey posthoc. 
Error bars: SEM. Scale Bar: 200μm. 
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Figure 6 Phenotypic analysis of R26RFgfr2c;act; Fgfr2cC342Y double mutants at E18.5. 
(A) R26RFgfr2c;act; Fgfr2cC342Y have a more severe phenotype of the external ear (box) compared to 
R26RFgfr2c;act (arrow). Inserts are magnified representations of the ear phenotype. (B) Craniofacial 
phenotype of the R26RFgfr2c;act; Fgfr2cC342Y. Wormian bone rescue in R26RFgfr2c;act; Fgfr2cC342Y and a 
wider frontal posterior interfrontal suture. Other features include severe tympanic ring hypoplasia and 
cleft palate. Bottom panels are ALP assays, notice partial sparing of the coronal suture in 
R26RFgfr2c;act; Fgfr2cC342Y. (C, D) Quantitative analysis of the calvarial bones. Significant size 
reduction of the frontal and parietal bones in R26RFgfr2c;act; Fgfr2cC342Y compared to Fgfr2cC342Y  
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(p<0.001 and p=0.016 respectively). Statistics: One way ANOVA with Tukey’s Posthoc ; Arrows 
indicate regions affected. Scale bar: 1mm.  
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Figure 7 Analysis of proliferation by phoshohistone-3 immunohistochemistry. 
(A) PHH3 staining (red) in sagittal sections through the coronal suture of R26RFgfr2c;act and 
Fgfr2cC342Y single mutants, and R26RFgfr2c;act; Fgfr2cC342Y double mutants shows an apparent 
increased number of proliferative cells in the suture mesenchyme (white arrowheads) of double 
mutants. (B) Quantification of the proliferation assay shows a statistically significant increase 
(P<0.05) in R26RFgfr2c;act; Fgfr2cC342Y double mutants alone compared to Fgfr2cC342Y. Scale bar is 
200µm. 
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Figure S1. Fgfr2c RNA and FGFR2c protein expression validation. 
(A) RT-qPCR analysis of Fgfr2c expression reveals upregulation of Fgfr2c transcripts by approximately 2-fold 
in R26RFgfr2c;βactin E12.5 embryos. (B) Immunoblot for the V5 epitope shows expression of the transgenic 
FGFR2cV5 protein in overexpression embryos only.  
Disease Models & Mechanisms: doi:10.1242/dmm.035311: Supplementary information
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Figure S2. Quantitative analysis of R26RFgfr2c;βact limb bones. 
(A) Whole mount skeletal stained limbs of control and R26RFgfr2c;βact E18.5 embryos show normal morphology. 
(B) Quantitative analysis shows no statistically significant difference between control and mutant limb size. 
Disease Models & Mechanisms: doi:10.1242/dmm.035311: Supplementary information
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Figure S3. Reporter activity of βactinCRE/+, Mesp1CRE/+ and Wnt1CRE/+.
eGFP (green) is only expressed in the event of CRE recombination in R26RmTmG, tdTomato (red) is expressed 
otherwise. Complete recombination is present in R26RmTmG/+; βactinCRE/+. Cells derived from the 
mesoderm are only present in the parietal bone of R26RmTmG/+;Mesp1CRE/+. Cells derived from the NCC 
lineage are only present in the frontal bone of Wnt1CRE/+;YFP mice. F:frontal bone, P: parietal bone; Scale 
bar: 200µm. 
Disease Models & Mechanisms: doi:10.1242/dmm.035311: Supplementary information
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Figure S4. Quantitative analysis of neural crest derivatives in the craniofacial skeleton shows a decrease in size 
of mandible (A) and nasal bones (B) in R26RFgfr2c;βact and R26RFgfr2c;Wnt1 E18.5 embryos.  Statistics: Student’s t-
test with Welch’s correction. 
Disease Models & Mechanisms: doi:10.1242/dmm.035311: Supplementary information
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